Astellas Pharma Inc
4503.T · Health Technology · Pharmaceuticals: Major · JP
15,883 employees · astellas.com/jp
About
Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases.
Annual results
Reported figures, JPY · revenue up 11.9% in 2026
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2026 | 2.1T | 292B | 13.6% | — |
| 2025 | 1.9T | 50.7B | 2.7% | — |
| 2024 | 1.6T | 17.0B | 1.1% | — |
| 2023 | 1.5T | 98.7B | 6.5% | — |
| 2022 | 1.3T | 124B | 9.6% | — |
Dividends per share
4503.T in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Astellas Pharma Inc are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.